局限性前列腺癌根治术中骨髓播散肿瘤细胞的多平台检测:罕见检出
研究在208例临床局限性前列腺癌根治术患者、16例对照和5例转移病例中,用4种平台检测骨髓播散肿瘤细胞。上皮标志物在对照中非特异性表达,以前列腺特异性标志物检测时局限性病例通常未检出播散肿瘤细胞。
要点
- 上皮标志物在骨髓中非特异性表达,不适用于播散肿瘤细胞检测。
- 以前列腺特异性标志物检测,局限性前列腺癌患者通常未检出播散肿瘤细胞。
- 多平台评估显示局限性患者骨髓播散肿瘤细胞罕见。
核心结论
- 多平台评估显示上皮标志物在骨髓中非特异性,不适用于播散肿瘤细胞检测;以前列腺特异性标志物检测,局限性前列腺癌患者通常未检出播散肿瘤细胞。
研究设计与样本
- 骨髓取自208例临床局限性病例、16例对照和5例转移病例,外周血取自37例转移病例。
- 样本在4个中心用4种不同平台评估:AdnaTest或VERSA抗体富集,或RareCyte或HD-SCA全样本检测,使用传统上皮标志物和前列腺特异性标志物。
主要发现
- 使用AdnaTest时,EpCAM、NKX3.1和AR在对照和大多数样本中非特异性表达,与围手术期变量无关。
- 仅1例局限性患者前列腺特异性标志物PSA阳性;VERSA平台无局限性病例检出播散肿瘤细胞。
- RareCyte和HD-SCA平台仅1例患者检出1个播散肿瘤细胞。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease and existing detection methods rely on epithelial markers with low specificity and sensitivity. We used multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy. MATERIALS AND METHODS: Bone marrow was harvested from 208 clinically localized cases, 16 controls and 5 metastatic cases with peripheral blood obtained from 37 metastatic cases. Samples were evaluated at 4 centers with 4 distinct platforms using antibody enrichment with the AdnaTest (Qiagen®) or VERSA (versatile exclusion based rare sample analysis), or whole sample interrogation with the RareCyte platform (Seattle, Washington) or HD-SCA (high definition single cell assay) using traditional epithelial markers and prostate specific markers. We investigated the sensitivity and specificity of these markers by evaluating expression levels in control and metastatic cases. RESULTS: EpCAM, NKX3.1 and AR were nonspecifically expressed in controls and in most samples using AdnaTest with no relation to perioperative variables. Only 1 patient with localized disease showed positive results for the prostate specific marker PSA. With the VERSA platform no localized case demonstrated disseminated tumor cells. With the RareCyte and HD-SCA platforms only a single patient had 1 disseminated tumor cell. CONCLUSIONS: Evaluation across multiple platforms revealed that epithelial markers are nonspecific in bone marrow and, thus, not suitable for disseminated tumor cell detection. Using prostate specific markers disseminated tumor cells were typically not detected in patients with localized prostate cancer.
引用
- Chalfin HJ, Glavaris SA, Malihi PD, et al. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol. 2018. PMID: 29339080. doi:10.1016/j.juro.2018.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。